We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Under the terms of the agreement, Glythera and Cancer Research UK will select and optimise toxins from the inhibitor payload series for development in ADCs.